Duzopharm, 50 mg 30 pcs.

Duzofarm is a drug that improves cerebral and peripheral blood circulation. It has a vasodilator effect. It decreases RPS and increases the cardiac output without significant effect on HR and BP. The vasodilatory effect of Dusopharm is a result of its direct myotropic action, antagonistic in relation to serotonin 5NT2 receptors and alpha-adrenoblocking action.

It has m-cholin-blocking action. It has a positive effect on cellular metabolism, improving oxygen and glucose utilization. This effect is due to its ability to increase ATP level and inhibit the enzyme succinate dehydrogenase. It activates glucose utilization through the citric acid cycle and increases the conversion of succinic acid into fumaric acid. As a result, it increases the resistance of cells (including the brain) to hypoxia. In addition, Dusofarm reduces the increased viscosity of the blood.

Pharmacokinetics

Intake

Duzofarm is almost completely absorbed when ingested. Food has almost no effect on its absorption. After a single dose of 100 mg, Cmax is observed after 45-60 min and is 175 mcg/ml. It is subject to hepatic recirculation, which contributes to its longer plasma retention.

Binding

Binding to blood proteins is 80%. It penetrates through the BBB. Cmax in brain tissue is reached after 60 min. After 24 hours after taking it, its concentration in brain tissue is 3 times higher than in plasma. There are no data on penetration of Dusofarm through the placenta and into the breast milk.

Metabolism

Metabolized mainly in the liver by hydrolysis, which is carried out by plasma esterases. The main metabolites studied are naphronic acid and diethylaminoethanol, which has a stimulating effect on the CNS.

The T1/2 is 1-2 hours with a single dose of 100 mg and 3.5 hours with a dose of 200 mg. It is eliminated from the body mainly through the intestine and in small amounts through the kidneys.

Pharmacokinetics in special clinical cases

There are no data about changes in its excretion rate in liver or kidney function disorders.

Age has no effect on the pharmacokinetic parameters of the drug.

Indications

Recuperation period of cerebral circulatory disorders; peripheral circulatory disorders (intermittent claudication, Raynaud’s disease, trophic ulcers).

Active ingredient

Composition

Active ingredient:

Naphthidrofuryl oxalate 50 mg;

Associates:

lactose monohydrate,

microcrystalline cellulose,

Wheat starch,

copovidone,

colloidal silicon dioxide,

Magnesium stearate,

talc;

Shell:

Titanium dioxide, talc, magnesium stearate, macrogol 6000, methacrylic acid and ethylacrylate copolymer, sunset yellow dye (E110)

How to take, the dosage

The drug is prescribed orally. The tablets should be swallowed whole with enough fluid (water).

In case of cerebral circulation disorders the drug is prescribed in a daily dose of 300 mg (2 tablets 3 times a day).

In peripheral circulation disorders the daily dose is 500-600 mg divided into 3 doses.

Duzofarm is recommended for long-term therapy (up to 6 months).

Dose adjustment in renal or hepatic insufficiency is not required.

Interaction

It enhances the hypotensive effect of antihypertensive drugs. In this regard, it is recommended to monitor BP more frequently at the beginning of treatment with Dusofarm and antihypertensive drugs simultaneously.

Contraindications

The drug should be prescribed with caution in closed-angle glaucoma, prostatic hyperplasia.

Side effects

Digestive system disorders: nausea, vomiting, epigastric pain, intestinal colic, diarrhea, decreased appetite, reversible increase in liver enzymes activity, gastric mucous membrane ulcers.

CNS disorders: headache, dizziness, sleep disturbance.

Other: allergic reactions.

Overdose

Symptoms: increased severity of side effects, ventricular arrhythmia, anxiety, decreased BP, bradycardia.

Treatment: gastric lavage, administration of activated charcoal and laxatives, symptomatic treatment. There is no specific antidote.